ENDRA Life Sciences Inc. - Kapitalisasi Buku NDRA

ENDRA Life Sciences (NDRA) generates revenue by implementing TAEUS ultrasound systems for liver fat analysis, replacing expensive MRI scans. This daily price chart available on the GURU.Markets page, which currently prices in 0.01, sits alongside risks stemming from software developed by major equipment manufacturers. However, expansion in the US is being hindered by FDA delays, despite the successful launch of pilot programs in Europe.

For ENDRA Life Sciences (NDRA), which monetizes an affordable MRI alternative for liver diagnostics, the balance sheet capitalization profile serves as an indicator of financial stability. This metric is calculated as the difference between total assets and liabilities, demonstrating the net value of the business; its trend on the chart determines the company's ability to withstand market shocks without losing operational independence while scaling its technologies.